2. Apoptosis Epigenetics Cell Cycle/DNA Damage
  3. Apoptosis HDAC
  4. HDAC-IN-31

HDAC-IN-31 is a potent, selective and orally active HDAC inhibitor with IC50s of 84.90, 168.0, 442.7, >10000 nM for HDAC1, HDAC2, HDAC3, HDAC8, respectively. HDAC-IN-31 induces apoptosis and cell cycle arrests at G2/M phase. HDAC-IN-31 shows good antitumor efficacy. HDAC-IN-31 has the potential for the research of diffuse large B-cell lymphoma.

For research use only. We do not sell to patients.

HDAC-IN-31 Chemical Structure

HDAC-IN-31 Chemical Structure

CAS No. : 1916505-13-9

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

HDAC-IN-31 Related Antibodies

Top Publications Citing Use of Products

View All HDAC Isoform Specific Products:

View All Isoforms
HDAC HDAC1 HDAC2 HDAC3 HDAC4 HDAC5 HDAC6 HDAC7 HDAC8 HDAC9 HDAC10 HDAC11 HD1 HD2

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

HDAC-IN-31 is a potent, selective and orally active HDAC inhibitor with IC50s of 84.90, 168.0, 442.7, >10000 nM for HDAC1, HDAC2, HDAC3, HDAC8, respectively. HDAC-IN-31 induces apoptosis and cell cycle arrests at G2/M phase. HDAC-IN-31 shows good antitumor efficacy. HDAC-IN-31 has the potential for the research of diffuse large B-cell lymphoma[1].

IC50 & Target[1]

HDAC1

84.90 nM (IC50)

HDAC2

168.0 nM (IC50)

HDAC3

442.7 nM (IC50)

HDAC8

>10000 nM (IC50)

In Vitro

HDAC-IN-31 (compound 24g) (2 µM) shows growth-inhibitory activities with the inhibition rate of 2.32%, 44.01%, 48.53%, 64.94% for TMD-8, HCT 116, A549, MDA-MB-231 cells[1].
HDAC-IN-31 (1 µM) shows selectivity with the IC50s of 84.9, 168.0, 442.7, >10000 nM for HDAC 1, HDAC 2, HDAC 3, HDAC 8, and 81.20%, 84.43%, 88.07%, 92.34%, 96.88%, 91.98% enzyme activity for HDAC4, HDAC 5,HDAC 7, HDAC9, HDAC 6, HDAC 11, respectively[1].
HDAC-IN-31 (2.5, 5, 7.5, 10 µM; 24 h) increases the expression of HDAC1, Ace-H3, Ace-H4, Cleaved PARP, Cleaved Caspase-3 in a dose-dependent manner[1].
HDAC-IN-31 (0-4 µM; 24 h)induce apoptosis and cell cycle arrests in G2/M phase in a dose-dependent manner[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

HDAC-IN-31 Related Antibodies

Cell Proliferation Assay[1]

Cell Line: MDA-MB-231, A549, NCI-H460, HCT-116,SK-OV-3, HT-29, COLO 678, NCI-H441, 22Rv1, 786-O, TMD-8, DOHH-2, CCRF-CEM, SU-DHL-2, REC-1, MOLT-4, HUT-78, RS4;11 cells
Concentration: 0-20 µM
Incubation Time: 72 h
Result: Showed a broad spectrum of antitumor activity with the IC50s of 2.29, 2.85, 1.58, 1.16, 3.17, 2.41, 8.02, 2.62, 1.14, 0.60, 0.31, 0.39, 0.48, 0.51, 0.33, 0.38, 0.80, 0.47 µM for MDA-MB-231, A549, NCI-H460, HCT-116, SK-OV-3, HT-29, COLO 678, NCI-H441, 22Rv1, 786-O, TMD-8, DOHH-2, CCRF-CEM, SU-DHL-2, REC-1, MOLT-4, HUT-78, RS4;11 cells, respectively.

Western Blot Analysis[1]

Cell Line: TMD-8 cells
Concentration: 2.5, 5, 7.5, 10 µM
Incubation Time: 24 h
Result: Promoted the HDAC1, HDAC2, HDAC3 substrate Ace-H3 and Ace-H4 acetylation with a dose-dependent manner.

Apoptosis Analysis[1]

Cell Line: TMD-8 cells
Concentration: 0.5, 1, 2, 4 µM
Incubation Time: 24 h
Result: Induced cell apoptosis at a concentration-dependent manner.

Cell Cycle Analysis[1]

Cell Line: TMD-8 cells
Concentration: 250, 500, 1000 nM
Incubation Time: 24 h
Result: Arrested the cell cycle at G2/M phase in a dose-dependent manner.
In Vivo

HDAC-IN-31 (2 mg/kg for i.v.; 10, 100 mg/kg for p.o.) shows good bioavailability with a significant dose dependent manner[1].
HDAC-IN-31 (50, 100 mg/kg; p.o, daily for 21 consecutive days) shows good antitumor efficacy in a TMD-8 xenograft model without obvious toxicity[1].
Pharmacokinetic Parameters of HDAC-IN-31 in mice[1].

Parameters Unit 24 g (25 mg/kg)
Cmax ng·h·mL-1 3100±231
T1/2(po) h 4.4±0.3
AUC0-inf(iv) ng·h·mL-1 1040±142
AUC0-inf(po) ng·h·mL-1 5180±252
MRTPO h 2.6±0.4
F % 39.9±2.1
ICR mouse; 2 mg/kg for i.v.; 25 mg/kg for p.o.[1].
Pharmacokinetic Parameters of HDAC-IN-31 in tumor models[1].
Parameters Unit po (25 mg/kg) po (50 mg/kg) po (100 mg/kg)
Cmax ng·h·mL-1 1700±317 14700±1024 10700±1001
AUC0-t ng·h·mL-1 1220±242 9710±314 9740±230
AUC0-inf ng·h·mL-1 1230±165 9730±341 9770±332
MRT0-t h 0.750±0.043 0.812±0.023 1.43±0.56
MRT0-inf h 0.805±0.086 0.821±0.041 1.51±0.32
Mouse; 25, 50, 100 mg/kg for p.o.[1].
Pharmacokinetic Parameters of HDAC-IN-31 in tumor models[1].
PK parameters Unit iv (2 mg/kg) po (10 mg/kg) po (100 mg/kg)
Cmax ng·h·mL-1 3960±413 58300±1352
T1/2 h 0.427±0.016 1.31±0.27 1.63±0.52
AUC0-inf ng·h·mL-1 1250±132 2670±286 57200±1047
MRT h 0.402±0.032 0.919±0.052 0.897±0.041
CL mL·kg·min-1 27.2±1.2
F % 45.6±1.2 91.8±2.3
ICR mice; 2 mg/kg for i.v.; 10, 100 mg/kg for p.o.[1].
Pharmacokinetic Parameters of HDAC-IN-31 in tumor models[1].
PK parameters Unit Monkey Dog
iv (1 mg/kg) po (10 mg/kg) iv (1 mg/kg) po (10 mg/kg)
Cmax ng·h·mL-1 8520±301 4740±243
T1/2 h 4.31±0.56 9.14±0.32 1.65±0.41 1.51±0.33
AUC0-inf ng·h·mL-1 15700±1842 53200±1241 2550±365 15100±2004
MRT h 3.41±0.12 8.28±0.32 2.26±0.41 2.71±0.32
CL mL·kg·min-1 1.35±0.21 6.72±0.35
Vdss L·kg-1 0.34±0.22 0.55±0.04
F % 27.6±2.1 58.9±1.2
Dogs and monkeys; 1 mg/kg for i.v., 10 mg/kg for p.o. for monkey; 1 mg/kg for i.v., 10 mg/kg for p.o. for dog[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: ICR mice[1]
Dosage: 2 mg/kg for i.v.; 25 mg/kg for p.o.(DMSO/PEG200/saline = 20:20:60, v/v/v)
Administration: I.v. or p.o.
Result: Showed high oral bioavailability (F=40%).
Animal Model: Mouse[1]
Dosage: 25, 50, 100 mg/kg
Administration: P.o.
Result: Did not exhibit a significant dose dependent for oral administration.
Animal Model: ICR mice[1]
Dosage: 2, 10, 100 mg/kg (into the form of hydrochloride)
Administration: 2 mg/kg for i.v.; 10, 100 mg/kg for p.o.
Result: Showed good bioavailability with a significant dose dependent.
Animal Model: Dogs and monkeys[1]
Dosage: 1, 10 mg/kg
Administration: 1 mg/kg for i.v.; 10 mg/kg for p.o.
Result: Showed good pharmacokinetic characteristics for different species.
Animal Model: 5-6 weeks, female CB.17 SCID mice (TMD-8 tumor xenografts)[1]
Dosage: 50, 100 mg/kg
Administration: P.o, daily for 21 consecutive days
Result: Inhibited the tumor growth with the inhibition rate of 77% and had no significant effect on the internal organs of mice at 100 mg/kg/d.
Molecular Weight

412.48

Formula

C25H24N4O2
CAS No.
SMILES

O=C(NC1=CC=CC=C1N)C2=CC=C(CN3C(/C(CCC3)=C/C4=NC=CC=C4)=O)C=C2
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

HDAC-IN-31 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

HDAC-IN-311916505-13-9ApoptosisHDACHistone deacetylasesdiffuse large B-cell lymphomaantitumorselectiveorally activeG2/MTMD-8 tumor xenograftsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
HDAC-IN-31
Cat. No.:
HY-144293
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.